2024 Partners
If you'd like to become a partner for the 3rd annual Liquid Biopsy Surveillance Summit. Get in touch here to partner and learn more about our bespoke sponsorship opportunities.
Program Partner
Burning Rock Dx (NASDAQ: BNR and LSE: BNR) is a global diagnostics company focusing on applying next-generation sequencing (NGS) technology in precision oncology. Burning Rock’s diverse portfolio operates out of their two CLIA/CAP laboratories in China and the United States, allowing for global clinical trial support. Burning Rock has achieved two NMPA-approved IVD kits, four assays with CE marking, and a breakthrough device designation (BDD) received from both US FDA and China NMPA for multi-cancer detection blood test. Leveraging their robust NGS technology and extensive experience in pharmaceutical and project partnerships, Burning Rock provides dedicated services to pharmaceutical partners, encompassing genomic data solutions, clinical trial solutions, precision patient recruitment, and companion diagnostics (CDx) development and commercialization.
Program Partner
Personalis, Inc. is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products. ACE Technology improves every individual step in the next-generation sequencing (NGS) process, from nucleic acid extraction to sequencing assays, to data analytics. This makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions that are missed with the use of conventional sequencing techniques. Using this comprehensive approach, we provide genomic data of the highest quality and accuracy to help biopharma drive their immuno-oncology clinical and biomarker discovery programs, thus enabling the rational design and development of effective cancer immunotherapies.
Program Partner
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care.
Program Partner
Natera has developed Signatera™, a tumor-informed circulating tumor DNA (ctDNA) assay for molecular residual disease (MRD) detection, recurrence monitoring, and treatment response monitoring in patients previously diagnosed with cancer. With >60 peer-reviewed publications and >260 congress presentations, Signatera™ is clinically validated across multiple cancer types and reimbursed by Medicare for colorectal cancer, muscle-invasive bladder cancer, and immunotherapy monitoring. Signatera™ is used in multiple on-going prospective studies led by drug developers and researchers, has FDA Breakthrough Device Designation and CE mark, and is available globally. Learn more at https://www.natera.com/clinical-trials
Program Partner
Wren is at the forefront of transforming cancer diagnostics through advanced mRNA technologies. Our pioneering machine learning-based liquid biopsy tests utilize multiplex mRNA expression to revolutionize cancer patient care and enhance clinical trials. Conducted in a CLIA-certified, CAP-accredited, and NYSDOH-licensed laboratory, our tests are governed by a robust quality management system.
Meeting Partner
BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to life science and diagnostic industries. Recognized as an industry leader, BioIVT specializes in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids.